Clever Leaves International Inc. (OTC: CLVR)
Building Consistency in Medical Cannabis Production

Medical cannabis production requires more than effective cultivation. Suppliers serving pharmaceutical manufacturers and regulated markets must deliver consistent products, meet stringent quality standards and comply with regulations governing cannabinoid production and distribution. Maintaining these requirements depends on control over each stage of production, from growing and processing cannabis to preparing materials for commercial use.

Clever Leaves International Inc. (OTC: CLVR) brings these stages together through an integrated production model focused on pharmaceutical-grade cannabinoids. Its cultivation and extraction operations in Colombia support a portfolio spanning cannabis flower, extracts, active pharmaceutical ingredients and finished formulations.

By connecting cultivation with processing, product development and regulatory expertise, Clever Leaves supplies business customers with products tailored to the needs of regulated markets.

Connecting Cultivation with Pharmaceutical Quality

Clever Leaves combines greenhouse cultivation, extraction and processing to control critical stages of production. This architecture supports customers seeking bulk cannabis materials as well as more sophisticated cannabinoid ingredients. The company’s agricultural cultivation is tailored to the specifications of medical cannabis products, as it is integrated with the downstream processing.

Greenhouse production takes advantage of Colombia’s location near the equator, where consistent natural sunlight reduces reliance on artificial lighting. Clever Leaves also uses recycled rainwater for irrigation, linking resource management with its cultivation operations. These practices form part of its production model, which balances agricultural output with the resources required to maintain facilities.

After harvesting, cannabis material moves into processing, where extraction produces cannabinoid ingredients for pharmaceutical and other regulated applications. Clever Leaves provides materials at various production stages for customers to select from based on their manufacturing needs. This capability links agricultural production to ingredients and formulations in product development, further down the supply chain.

Quality assurance underpins these activities. Clever Leaves holds EU GMP certification for its extraction operations, alongside GMP certification from Colombia’s National Food and Drug Surveillance Institute, Instituto Nacional de Vigilancia de Medicamentos y Alimentos certification and Good Agricultural and Collection Practices certification. These credentials support its work in markets where documented production controls and recognized quality standards are important.

Scaling Production without Losing Consistency

Clever Leaves’ operations in Colombia amount to over 1.8 million square feet of growing capacity and can produce 104,400 kilograms of dried flower per year. This infrastructure supports customers requiring large volumes of cannabis-derived materials.
It also uses seed-to-sale tracking systems to maintain visibility into production. Tracking from plant propagation through subsequent stages helps document the origin and handling of materials, supporting operational oversight and traceability. These records are particularly relevant when customers require information about how products were cultivated and processed.

Cost efficiency is another consideration in the production model. The use of natural sunlight is beneficial to greenhouse cultivation, and the agricultural conditions and operating costs in Colombia support the economics of production. These factors provide a competitive advantage, enabling it to supply cannabis products without relying solely on traditional indoor cultivation methods.

Scale alone, however, does not determine whether a supplier meets customer specifications. Processing methods and quality controls must deliver the required characteristics in the final material. Clever Leaves combines its cultivation infrastructure with extraction and processing capabilities to offer products ranging from cannabis flower to refined ingredients and finished formulations.

Developing Products around Customer Requirements

Medical cannabis businesses require different ingredients, cannabinoid profiles and product formats depending on their applications. Clever Leaves serves these varied needs through a portfolio that includes cannabidiol and tetrahydrocannabinol products, full-spectrum and broad-spectrum extracts, standardized extracts, distillates and oral solutions. This range gives customers options for sourcing ingredients and formulations suited to their manufacturing plans.

White-label and private-label services take it a step further, allowing businesses to build products under their own brand names. Clever Leaves can help customers who want more developed formulations, not just supplying agricultural materials. This structure aligns its production capabilities with the commercial needs of companies looking to bring cannabinoid products to market.

Research and development support work on product development, genetics and cultivation methods. Clever Leaves identifies these areas as priorities for adapting its portfolio to customer needs and regulatory requirements. Its teams bring together expertise in cultivation, extraction, quality assurance and regulatory affairs, supporting collaboration on product specifications and manufacturing considerations.

The ability to customize formulas allows Clever Leaves to work with customers on specific needs. A customer requiring a specific cannabinoid profile or finished products format may need more than a general-purpose ingredient. Collaboration on specifications helps align production capabilities with those requirements, subject to the applicable regulatory framework.

Navigating International Regulatory Requirements

Medical cannabis products must meet the rules of the markets in which they are supplied. Requirements governing quality, importation, documentation and distribution differ by jurisdiction, making regulatory knowledge an important part of international production. Manufacturers must account for these conditions before products can move from processing facilities to customers.
Clever Leaves reports successful shipments to more than 15 countries and identifies regulatory compliance as a core capability supporting international business. Its certifications and experience supplying overseas markets contribute to its ability to work with customers operating under different requirements. Market access nevertheless depends on the rules and approvals applicable to each product and destination.

Its production operations remain centered in Colombia, and commercial activities include Germany, Australia and Israel. In Germany, Clever Leaves has partnered with Cansativa, a licensed importer and distributor of medical cannabis products. The relationship supports its participation in a market with specific regulatory requirements on importation and distribution.

Clever Leaves has also reported commercial relationships in Australia to provide cannabis flower and finished products. These activities demonstrate the effects of aligning production specifications and documentation to the requirements of individual markets. Its regulatory expertise helps business customers navigate the conditions under which a product can be offered, and is complemented by manufacturing capacity.

Integrating Efficiency with Responsible Production

Clever Leaves connects its cultivation and processing operations with environmental and community priorities. Greenhouse production, natural sunlight and rainwater reuse form part of its approach to resource management. Its sustainability materials report that the company achieved an international declaration of carbon neutrality in 2023, reflecting efforts to measure emissions, reduce its carbon footprint and offset remaining emissions.

Local employment is another part of its reported impact. Clever Leaves states that more than 90 percent of its workers come from local communities and that its cultivation and extraction operations support employment in the regions where they are based. Its sustainability priorities also include responsible employment, water conservation and environmental management.

These commitments sit alongside the requirements of producing medical cannabis at scale. Agricultural conditions, processing controls and resource management all influence the operation of a production facility. Clever Leaves brings these considerations into a business model serving customers that require cannabinoid materials and formulations for regulated markets.

Clever Leaves’ recognition as the Top Medical Cannabis Production Company 2026 reflects its work in cultivation, extraction, product development and regulatory compliance. By supplying products at different stages of the manufacturing process and supporting customers operating in international markets, the company has established a production model built around the needs of the medical cannabis supply chain.